On February 17, 2023, the U.S. Food and Drug Administration (FDA) approved a groundbreaking treatment to treat geographic atrophy (GA), an advanced form of dry macular degeneration (AMD).
Share, comment, bookmark or report
Both Yesafili and Opuviz are used to treat: Neovascular (wet) age-related macular degeneration. Macular edema following retinal vein occlusion. Diabetic macular edema. Diabetic retinopathy.
Share, comment, bookmark or report
New treatments for macular degeneration may help preserve your eyesight for longer, without the need for frequent injections. Some of these treatments include retinal gene therapy and the"port" delivery system.
Share, comment, bookmark or report
Treatment for neovascular age-related macular degeneration (nAMD) has evolved rapidly over the past decade, during which pivotal trials have established the efficacy of vascular endothelial growth ...
Share, comment, bookmark or report
These potential treatments range from molecules that quell damaging inflammation to stem-cell-based therapies that aim to partially replenish lost epithelial cells at sites affected by geographic...
Share, comment, bookmark or report
NORTHAMPTON, Ma., Dec. 19, 2023 — The American Macular Degeneration Foundation received news that the first patient has been dosed in a safety and efficacy clinical trial of a one-time gene therapy treatment for advanced dry macular degeneration (dry AMD), also known as Geographic Atrophy (GA).
Share, comment, bookmark or report
A groundbreaking, new frontier in macular degeneration treatment has been announced! With the FDA’s approval of Syfovre™, for the first time there’s hope to preserve sight for millions of patients with the advanced stage of dry macular degeneration (dry AMD), called geographic atrophy (GA).
Share, comment, bookmark or report
Phase 3 clinical trials of a treatment known as photobiomodulation (PBM) have demonstrated sustained improvement in vision and a reduction in rates of new geographic atrophy in patients with intermediate dry AMD across two years.
Share, comment, bookmark or report
The latest research suggests most patients can go 3 to 4 months between treatments with Vabysmo. It may also be possible to combine two drugs and hit wet AMD with a double punch. These combos could further improve vision and make injections last longer.
Share, comment, bookmark or report
Blindness and could lead to an ‘off-the-shelf’ treatment within five years. The first patients to receive a new treatment derived from stem cells for people with wet age-related macular degeneration (AMD) have regained reading vision.
Share, comment, bookmark or report
Comments